Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management : A PIONEER Analysis Based on Big Data
(2023) In European Urology- Abstract
Background: Conservative management is an option for prostate cancer (PCa) patients either with the objective of delaying or even avoiding curative therapy, or to wait until palliative treatment is needed. PIONEER, funded by the European Commission Innovative Medicines Initiative, aims at improving PCa care across Europe through the application of big data analytics. Objective: To describe the clinical characteristics and long-term outcomes of PCa patients on conservative management by using an international large network of real-world data. Design, setting, and participants: From an initial cohort of >100 000 000 adult individuals included in eight databases evaluated during a virtual study-a-thon hosted by PIONEER, we identified... (More)
Background: Conservative management is an option for prostate cancer (PCa) patients either with the objective of delaying or even avoiding curative therapy, or to wait until palliative treatment is needed. PIONEER, funded by the European Commission Innovative Medicines Initiative, aims at improving PCa care across Europe through the application of big data analytics. Objective: To describe the clinical characteristics and long-term outcomes of PCa patients on conservative management by using an international large network of real-world data. Design, setting, and participants: From an initial cohort of >100 000 000 adult individuals included in eight databases evaluated during a virtual study-a-thon hosted by PIONEER, we identified newly diagnosed PCa cases (n = 527 311). Among those, we selected patients who did not receive curative or palliative treatment within 6 mo from diagnosis (n = 123 146). Outcome measurements and statistical analysis: Patient and disease characteristics were reported. The number of patients who experienced the main study outcomes was quantified for each stratum and the overall cohort. Kaplan-Meier analyses were used to estimate the distribution of time to event data. Results and limitations: The most common comorbidities were hypertension (35–73%), obesity (9.2–54%), and type 2 diabetes (11–28%). The rate of PCa-related symptomatic progression ranged between 2.6% and 6.2%. Hospitalization (12–25%) and emergency department visits (10–14%) were common events during the 1st year of follow-up. The probability of being free from both palliative and curative treatments decreased during follow-up. Limitations include a lack of information on patients and disease characteristics and on treatment intent. Conclusions: Our results allow us to better understand the current landscape of patients with PCa managed with conservative treatment. PIONEER offers a unique opportunity to characterize the baseline features and outcomes of PCa patients managed conservatively using real-world data. Patient summary: Up to 25% of men with prostate cancer (PCa) managed conservatively experienced hospitalization and emergency department visits within the 1st year after diagnosis; 6% experienced PCa-related symptoms. The probability of receiving therapies for PCa decreased according to time elapsed after the diagnosis.
(Less)
- author
- author collaboration
- organization
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- in press
- subject
- keywords
- Big data, Conservative management, Outcomes, PIONEER, Prostate cancer, Survival
- in
- European Urology
- publisher
- Elsevier
- external identifiers
-
- pmid:37414703
- scopus:85164440972
- ISSN
- 0302-2838
- DOI
- 10.1016/j.eururo.2023.06.012
- language
- English
- LU publication?
- yes
- id
- c9f8f8e1-228f-47be-b258-aa6ebe442d39
- date added to LUP
- 2023-10-06 14:33:49
- date last changed
- 2024-04-19 02:02:02
@article{c9f8f8e1-228f-47be-b258-aa6ebe442d39,
abstract = {{<p>Background: Conservative management is an option for prostate cancer (PCa) patients either with the objective of delaying or even avoiding curative therapy, or to wait until palliative treatment is needed. PIONEER, funded by the European Commission Innovative Medicines Initiative, aims at improving PCa care across Europe through the application of big data analytics. Objective: To describe the clinical characteristics and long-term outcomes of PCa patients on conservative management by using an international large network of real-world data. Design, setting, and participants: From an initial cohort of >100 000 000 adult individuals included in eight databases evaluated during a virtual study-a-thon hosted by PIONEER, we identified newly diagnosed PCa cases (n = 527 311). Among those, we selected patients who did not receive curative or palliative treatment within 6 mo from diagnosis (n = 123 146). Outcome measurements and statistical analysis: Patient and disease characteristics were reported. The number of patients who experienced the main study outcomes was quantified for each stratum and the overall cohort. Kaplan-Meier analyses were used to estimate the distribution of time to event data. Results and limitations: The most common comorbidities were hypertension (35–73%), obesity (9.2–54%), and type 2 diabetes (11–28%). The rate of PCa-related symptomatic progression ranged between 2.6% and 6.2%. Hospitalization (12–25%) and emergency department visits (10–14%) were common events during the 1st year of follow-up. The probability of being free from both palliative and curative treatments decreased during follow-up. Limitations include a lack of information on patients and disease characteristics and on treatment intent. Conclusions: Our results allow us to better understand the current landscape of patients with PCa managed with conservative treatment. PIONEER offers a unique opportunity to characterize the baseline features and outcomes of PCa patients managed conservatively using real-world data. Patient summary: Up to 25% of men with prostate cancer (PCa) managed conservatively experienced hospitalization and emergency department visits within the 1st year after diagnosis; 6% experienced PCa-related symptoms. The probability of receiving therapies for PCa decreased according to time elapsed after the diagnosis.</p>}},
author = {{Gandaglia, Giorgio and Pellegrino, Francesco and Golozar, Asieh and De Meulder, Bertrand and Abbott, Thomas and Achtman, Ariel and Imran Omar, Muhammad and Alshammari, Thamir and Areia, Carlos and Asiimwe, Alex and Beyer, Katharina and Bjartell, Anders and Campi, Riccardo and Cornford, Philip and Falconer, Thomas and Feng, Qi and Gong, Mengchun and Herrera, Ronald and Hughes, Nigel and Hulsen, Tim and Kinnaird, Adam and Lai, Lana Y.H. and Maresca, Gianluca and Mottet, Nicolas and Oja, Marek and Prinsen, Peter and Reich, Christian and Remmers, Sebastiaan and Roobol, Monique J. and Sakalis, Vasileios and Seager, Sarah and Smith, Emma J. and Snijder, Robert and Steinbeisser, Carl and Thurin, Nicolas H. and Hijazy, Ayman and van Bochove, Kees and Van den Bergh, Roderick C.N. and Van Hemelrijck, Mieke and Willemse, Peter Paul and Williams, Andrew E. and Zounemat Kermani, Nazanin and Evans-Axelsson, Susan and Briganti, Alberto and N'Dow, James}},
issn = {{0302-2838}},
keywords = {{Big data; Conservative management; Outcomes; PIONEER; Prostate cancer; Survival}},
language = {{eng}},
publisher = {{Elsevier}},
series = {{European Urology}},
title = {{Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management : A PIONEER Analysis Based on Big Data}},
url = {{http://dx.doi.org/10.1016/j.eururo.2023.06.012}},
doi = {{10.1016/j.eururo.2023.06.012}},
year = {{2023}},
}